OTCMKTS:TEAR - TearLab Stock Price, News, & Analysis Sign in or create an account to add this stock to your watchlist. Get Started $0.0821 -0.01 (-10.86 %) (As of 02/18/2019 02:53 AM ET)Previous Close$0.0821Today's Range$0.0821 - $0.115052-Week Range$0.03 - $0.3450Volume29,280 shsAverage Volume18,969 shsMarket Capitalization$960,323.70P/E RatioN/ADividend YieldN/ABeta1.72 ProfileDiscussionAnalyst RatingsChartEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesSEC FilingsSocial Media Share on FacebookShare on TwitterShare on LinkedInShare on RedditShare on StocktwitsPrint this articleShare by Email TearLab Corporation operates as an in-vitro diagnostic company in the United States and internationally. It offers TearLab Osmolority System, a proprietary in vitro diagnostic tear testing platform that measures tear film osmolarity for the diagnosis of dry eye disease; and enables eye care practitioners to test for sensitive and specific biomarkers using nanoliters of tear film at the point-of-care. Its TearLab Osmolarity System consists of TearLab disposable, a single-use microfluidic microchip; TearLab pen, a hand-held device that interfaces with the TearLab disposable; and TearLab reader, a small desktop unit that allows for the docking of the TearLab pen, as well as provides a quantitative reading for the operator. The company was formerly known as OccuLogix, Inc. TearLab Corporation was founded in 1996 and is headquartered in San Diego, California. Receive TEAR News and Ratings via Email Sign-up to receive the latest news and ratings for TEAR and its competitors with MarketBeat's FREE daily newsletter. Industry, Sector and Symbol Stock Exchange OTCMKTS Industry Surgical & medical instruments Sub-IndustryN/A SectorMedical Current SymbolOTCMKTS:TEAR Previous SymbolNASDAQ:TEAR CUSIPN/A Webwww.tearlab.com Phone858-455-6006Debt Debt-to-Equity RatioN/A Current Ratio0.81 Quick Ratio0.69Price-To-Earnings Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/A Sales & Book Value Annual Sales$27.12 million Price / Sales0.04 Cash FlowN/A Price / Cash FlowN/A Book Value($2.32) per share Price / Book-0.04Profitability EPS (Most Recent Fiscal Year)N/A Net Income$-16,100,000.00 Net Margins-22.03% Return on EquityN/A Return on Assets-38.48%Miscellaneous Employees42 Outstanding Shares11,697,000Market Cap$960,323.70 OptionableNot Optionable TearLab (OTCMKTS:TEAR) Frequently Asked Questions What is TearLab's stock symbol? TearLab trades on the OTCMKTS under the ticker symbol "TEAR." When did TearLab's stock split? How did TearLab's stock split work? TearLab's stock reverse split on the morning of Friday, February 24th 2017. The 1-10 reverse split was announced on Friday, February 24th 2017. The number of shares owned by shareholders was adjusted after the market closes on Thursday, February 23rd 2017. An investor that had 100 shares of TearLab stock prior to the reverse split would have 10 shares after the split. How were TearLab's earnings last quarter? TearLab Corp (OTCMKTS:TEAR) posted its quarterly earnings results on Thursday, August, 9th. The medical research company reported ($0.06) earnings per share (EPS) for the quarter. The medical research company had revenue of $6.41 million for the quarter. View TearLab's Earnings History. When is TearLab's next earnings date? TearLab is scheduled to release their next quarterly earnings announcement on Friday, March 1st 2019. View Earnings Estimates for TearLab. Has TearLab been receiving favorable news coverage? News coverage about TEAR stock has been trending somewhat positive this week, InfoTrie reports. The research group identifies positive and negative media coverage by monitoring more than six thousand news and blog sources in real time. The firm ranks coverage of companies on a scale of negative five to positive five, with scores closest to five being the most favorable. TearLab earned a news impact score of 1.4 on InfoTrie's scale. They also assigned media headlines about the medical research company a news buzz of 1.0 out of 10, indicating that recent media coverage is extremely unlikely to have an impact on the stock's share price in the next few days. Who are some of TearLab's key competitors? Some companies that are related to TearLab include Encision (ECIA), Delcath Systems (DCTH), Cytori Therapeutics (CYTX), Regenicin (RGIN), Amedica (AMDA), Cytocore (MDIT), AdvanSource Biomaterials Corpration (ASNB), Calmare Therapeutics (CTTC), Scivanta Medical (SCVM), Quantrx Biomedical (QTXB), Hypertension Diagnostics (HDII), Oncologix Tech (OCLG), Lombard Medical (EVARF), Revolutions Medical (RMCP) and Delcath Systems (DCTHD). Who are TearLab's key executives? TearLab's management team includes the folowing people: Mr. Elias Vamvakas, Exec. Chairman & Sec. (Age 60)Mr. Joseph S. Jensen, CEO & Director (Age 47)Mr. Michael Marquez, Chief Financial Officer (Age 37)Dr. Benjamin Sullivan Ph.D., Chief Scientific Officer (Age 43)Mr. Sam Fakhoury, VP of Quality, Compliance & Supply Chain How do I buy shares of TearLab? Shares of TEAR can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab. What is TearLab's stock price today? One share of TEAR stock can currently be purchased for approximately $0.0821. How big of a company is TearLab? TearLab has a market capitalization of $960,323.70 and generates $27.12 million in revenue each year. TearLab employs 42 workers across the globe. What is TearLab's official website? The official website for TearLab is http://www.tearlab.com. How can I contact TearLab? TearLab's mailing address is 150 La Terraza Blvd. Suite 101, Escondido CA, 92025. The medical research company can be reached via phone at 858-455-6006 or via email at [email protected] MarketBeat Community Rating for TearLab (OTCMKTS TEAR)Community Ranking: 3.1 out of 5 ( )Outperform Votes: 314 (Vote Outperform)Underperform Votes: 194 (Vote Underperform)Total Votes: 508MarketBeat's community ratings are surveys of what our community members think about TearLab and other stocks. Vote "Outperform" if you believe TEAR will outperform the S&P 500 over the long term. Vote "Underperform" if you believe TEAR will underperform the S&P 500 over the long term. You may vote once every thirty days. This page was last updated on 2/18/2019 by MarketBeat.com StaffFeatured Article: What is an investor looking for in an SEC filing?